Display options
Share it on

J Cardiovasc Electrophysiol. 2022 Jan;33(1):30-31. doi: 10.1111/jce.15301. Epub 2021 Dec 06.

Cutting through the fat: Relationship between comorbidities and arrhythmias in hypertrophic cardiomyopathy.

Journal of cardiovascular electrophysiology

Alan Sugrue, David Lin

Affiliations

  1. Cardiovascular Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

PMID: 34845783 DOI: 10.1111/jce.15301

[No abstract available.]

Keywords: atrial arrhythmias; atrial fibrillation; cardiac arrest; hypertrophic cardiomyopathy; sudden death

References

  1. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):e159-e240. - PubMed
  2. Finocchiaro G, Magavern E, Sinagra G, et al. Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy. J Am Heart Assoc. 2017;6(12). - PubMed
  3. Olivotto I, Maron BJ, Tomberli B, et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62(5):449-457. - PubMed
  4. Nerbass FB, Pedrosa RP, Danzi-Soares NJ, Drager LF, Arteaga-Fernandez E, Lorenzi-Filho G. Obstructive sleep apnea and hypertrophic cardiomyopathy: a common and potential harmful combination. Sleep Med Rev. 2013;17(3):201-206. - PubMed
  5. Javed S, Gupta D, Lip GYH. Obesity and atrial fibrillation: making inroads through fat. Eur Heart J Cardiovasc Pharmacother. 2021;7(1):59-67. - PubMed
  6. Linz D, McEvoy RD, Cowie MR, et al. Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review. JAMA Cardiol. 2018;3(6):532-540. - PubMed
  7. Sridharan A, Maron MS, Carrick RT, et al. Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2021. https://doi.org/10.1111/jce.15304 - PubMed
  8. Fumagalli C, Maurizi N, Day SM, et al. Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy. JAMA Cardiol. 2020;5(1):65-72. - PubMed
  9. Nollet EE, Westenbrink BD, de Boer RA, Kuster DWD, van der Velden J. Unraveling the genotype-phenotype relationship in hypertrophic cardiomyopathy: obesity-related cardiac defects as a major disease modifier. J Am Heart Assoc. 2020;9(22):e018641. - PubMed
  10. Vyas V, Hunter RJ, Longhi MP, Finlay MC. Inflammation and adiposity: new frontiers in atrial fibrillation. Europace. 2020;22(11):1609-1618. - PubMed
  11. Ernault AC, Meijborg VMF, Coronel R. Modulation of cardiac arrhythmogenesis by epicardial adipose tissue: JACC state-of-the-art review. J Am Coll Cardiol. 2021;78(17):1730-1745. - PubMed
  12. Muhib S, Fujino T, Sato N, Hasebe N. Epicardial adipose tissue is associated with prevalent atrial fibrillation in patients with hypertrophic cardiomyopathy. Int Heart J. 2013;54(5):297-303. - PubMed

Publication Types